First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature
暂无分享,去创建一个
C. Doglioni | M. Roncarolo | A. Aiuti | M. Ponzoni | F. Ciceri | F. Barzaghi | R. Nicoletti | M. Cicalese | M. Migliavacca | A. Assanelli | R. Pajno | F. Giglio | F. Ferrua | M. Frittoli | I. Brigida | F. Dionisio | Miriam Casiraghi | J. Peccatori
[1] P. Zinzani,et al. Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. , 2017, Cancer treatment reviews.
[2] A. Aiuti,et al. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug. , 2017, Human gene therapy.
[3] A. Aiuti,et al. Long-Term Outcome of Adenosine Deaminase-Deficient Patients—a Single-Center Experience , 2017, Journal of Clinical Immunology.
[4] L. Leocani,et al. Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients , 2017, Scientific Reports.
[5] J. Puck,et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2016, Blood.
[6] GenelFerah,et al. Adenosine Deaminase-Deficient Severe Combined Immunodeficiency and Diffuse Large B-Cell Lymphoma , 2015 .
[7] A. Aiuti,et al. Progress in gene therapy for primary immunodeficiencies using lentiviral vectors , 2014, Current opinion in allergy and clinical immunology.
[8] P. Veys,et al. How I treat severe combined immunodeficiency. , 2013, Blood.
[9] F. Candotti,et al. Immunodeficiency Due to Defects of Purine Metabolism , 2013 .
[10] Aaron R Cooper,et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. , 2012, Blood.
[11] A. Fischer,et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. , 2012, Blood.
[12] A. Aiuti,et al. Autoimmune Dysregulation and Purine Metabolism in Adenosine Deaminase Deficiency , 2012, Front. Immun..
[13] Y. Yatomi. [From FAB classification to WHO classification of tumors of hematopoietic and lymphoid tissue]. , 2012, Rinsho byori. The Japanese journal of clinical pathology.
[14] Kathryn L. Parsley,et al. Hematopoietic Stem Cell Gene Therapy for Adenosine Deaminase–Deficient Severe Combined Immunodeficiency Leads to Long-Term Immunological Recovery and Metabolic Correction , 2011, Science Translational Medicine.
[15] M. Chiarini,et al. The Different Extent of B and T Cell Immune Reconstitution after Hematopoietic Stem Cell Transplantation and Enzyme Replacement Therapies in SCID Patients with Adenosine Deaminase Deficiency , 2010, The Journal of Immunology.
[16] A. Aiuti,et al. Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase. , 2007, The Journal of pediatrics.
[17] U. Pannicke,et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. , 2007, Blood.
[18] M. Hershfield,et al. Cerebral Lymphoma in an Adenosine Deaminase–Deficient Patient With Severe Combined Immunodeficiency Receiving Polyethylene Glycol–Conjugated Adenosine Deaminase , 2005, Pediatrics.
[19] H. Takada,et al. Immunological aspects of Epstein-Barr virus infection. , 2002, Critical reviews in oncology/hematology.
[20] L. Notarangelo,et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement , 2002, Nature Medicine.
[21] A. Al-ghonaium,et al. Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy. , 2002, Blood.
[22] E. Macintyre,et al. Lymphoproliferative disorders in children with primary immunodeficiencies: immunological status may be more predictive of the outcome than other criteria , 2001, Histopathology.
[23] S. Rosenberg,et al. T Lymphocyte-Directed Gene Therapy for ADA− SCID: Initial Trial Results After 4 Years , 1995, Science.
[24] Evelina Mazzolari,et al. Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients , 1995, Science.
[25] K. Weinberg,et al. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase. , 1993, The Journal of clinical investigation.
[26] W. Borkowsky,et al. Novel deletion and a new missense mutation (Glu 217 Lys) at the catalytic site in two adenosine deaminase alleles of a patient with neonatal onset adenosine deaminase- severe combined immunodeficiency. , 1992, Journal of immunology.
[27] R. Hirschhorn,et al. Pathologic findings in adenosine deaminase deficient-severe combined immunodeficiency. II. Thymus, spleen, lymph node, and gastrointestinal tract lymphoid tissue alterations. , 1989, The American journal of pathology.
[28] R. Good,et al. Lymphoma in a patient with severe combined immunodeficiency with adenosine deaminase deficiency, following unsustained engraftment of histoincompatible T cell-depleted bone marrow. , 1986, The Journal of pediatrics.
[29] D. Kohn. Gene therapy for childhood immunological diseases , 2008, Bone Marrow Transplantation.
[30] H. Riess,et al. Immunosurveillance, immunodeficiency and lymphoproliferations. , 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[31] M. Yamada,et al. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. , 1998, Blood.
[32] Y. Sakiyama. [Gene therapy for adenosine deaminase deficiency]. , 1996, [Hokkaido igaku zasshi] The Hokkaido journal of medical science.
[33] H. Bobby Gaspar,et al. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID) , 2009, Biologics : targets & therapy.